The case was seen as a test of a more aggressive policy by the agency.
Related Posts
Eli Lilly Bets $2.4 Billion on Orna Therapeutics to Advance In Vivo Cell Therapies
Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion in cash, securing access to proprietary circular RNA technology for in vivo cell engineering in autoimmune diseases and oncology....
Novartis Doubles Down on Early-Stage M&A Strategy as Near-Launch Assets Become Scarce
null Novartis is reinforcing its commitment to acquiring early-stage pipeline assets and clinical-stage candidates, even as the pharmaceutical giant faces intensifying competition for late-stage drug...
Mubadala Exits Arcadia Consumer Healthcare as Bansk Group Assumes Full Control in Continuation Vehicle
Mubadala Capital has sold its minority stake in Arcadia Consumer Healthcare to funds managed by Bansk Group, marking the end of a four-year partnership that tripled the platform's revenue and...
Revolution Medicines Stock Plunges 20% as Merck Ends $28-32 Billion Acquisition Talks Over Valuation Rift
Merck & Co. has terminated acquisition discussions with Revolution Medicines after failing to agree on price for a potential $28-32 billion deal, triggering a 20% drop in Revolution's shares and...